The FDA previously granted breakthrough therapy designation to ziftomenib for relapsed/refractory NPM1-mutant AML.

In a landmark decision poised to revolutionize drug development, the U.S. Food and Drug Administration (FDA) has announced a ...

NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine ...

I called RFK Jr. an "extinction-level" threat to US biomedical science and public health. That extinction is under way.

Cruelty Free International welcomes major shift towards humane, modern approaches to drug development and testing ...

The move comes after lawmakers sought to force the agency to update regulations that would allow alternatives to animal ...

Fate Therapeutics (NASDAQ:FATE) announced that the U.S. FDA granted Regenerative Medicine Advanced Therapy designation to ...